




Good Practice Guide

Comparator Management



Connecting a World of Pharmaceutical Knowledge





Good Practice Guide

Comparator Management

Disclaimer:

This Guide describes sourcing and procuring comparators for use in a clinical trial. ISPE cannot ensure and does not warrant that this guidance replaces any existing or future regulatory requirements.

Limitation of Liability

In no event shall ISPE or any of its affiliates, or the officers, directors, employees, members, or agents of each of them, be liable for any damages of any kind, including without limitation any special, incidental, indirect, or consequential damages, whether or not advised of the possibility of such damages, and on any theory of liability whatsoever, arising out of or in connection with the use of this information.

© Copyright ISPE 2012. All rights reserved.

No part of this document may be reproduced or copied in any form or by any means – graphic, electronic, or mechanical, including photocopying, taping, or information storage and retrieval systems – without written permission of ISPE.

All trademarks used are acknowledged.

ISBN 978-1-936379-33-0

Preface

The Purpose of the ISPE Good Practice Guide: Comparator Management is intended to establish strategic and tactical considerations when sourcing and procuring comparators for use in a Clinical Trial.

The information provided in this Guide reflects the cumulative knowledge and experiences of the authors, editors, and reviewers with input from members of the ISPE Investigational Products (IP) Community of Practice (COP) and general membership.

Acknowledgements

This Good Practice Guide was produced by a Task Team led by Henryk Junker of Allergan, and Mark Ware of Idis. The work was supported by the ISPE Investigational Products (IP) Community of Practice (COP).

Document Core Task Team Members

Eva-Maria Borchert	Sanofi-Aventis	Germany
Chris Butta	Pfizer	USA
Henryk Junker	Allergan	United Kingdom
Sarbari Roy	Astra Zeneca	Sweden
Julie Swarts	Eli Lilly	USA
Mark Ware	Idis	USA/United Kingdom

The Task Team also wishes to thank Tiffany Cavallaro of Merck for her contributions during the early stages of development, the review team for their comments, and ISPE for technical writing and editing support by Gail Evans (ISPE Guidance Documents Writer/Editor).



**Connecting a World of
Pharmaceutical Knowledge**

ISPE Headquarters

600 N. Westshore Blvd., Suite 900, Tampa, Florida 33609 USA
Tel: +1-813-960-2105, Fax: +1-813-264-2816

ISPE Asia Pacific Office

73 Bukit Timah Road, #04-01 Rex House, Singapore 229832
Tel: +65-6496-5502, Fax: +65-6336-6449

ISPE China Office

Suite 2302, Wise Logic International Center
No. 66 North Shan Xi Road, Shanghai, China 200041
Tel +86-21-5116-0265, Fax +86-21-5116-0260

ISPE European Office

Avenue de Tervueren, 300, B-1150 Brussels, Belgium
Tel: +32-2-743-4422, Fax: +32-2-743-1550

www.ISPE.org

Table of Contents

1	Introduction	7
1.1	Overview	7
1.2	Scope	7
1.3	Purpose	8
1.4	Benefits	8
1.5	Key Concepts	9
2	Comparator Drugs Sourcing Process	13
2.1	Introduction	13
2.2	Stakeholders in the Selection of a Comparator	13
2.3	Identification of the Supply Strategy to be Used	15
2.4	The Planning Stage	23
2.5	Establishing a Preferred Supplier Pool	25
2.6	Sourcing Options	26
3	Technical Considerations	31
3.1	Common Blinding Techniques	31
3.2	Decision Tree for Blinding	38
3.3	Classifying Methods of Blinding	39
3.4	Qualification Strategy	40
4	Release of Comparator	45
4.1	Quality Control and Stability Testing	45
4.2	Regulatory Requirements for the Release of Comparators	48
5	Appendix 1 – Request for Information	53
6	Appendix 2 – Suggested Release and Stability Testing Based on Modification	57
6.1	Negligible Stability Risk	58
6.2	Low Stability Risk	58
6.3	Moderate to High Stability Risk	59
7	Appendix 3 – Blinding and Dissolution Qualification Strategies	61
7.1	Determination of Blinding Method	62
8	Appendix 4 – Sources for Dissolution Method and Reference Material Information ...	65
9	Appendix 5 – List of Documents	67
10	Appendix 6 – References	69
11	Appendix 7 – Glossary	73
11.1	Acronyms	74
11.2	Definitions	77

1 Introduction

1.1 Overview

A comparator drug, also known as a reference drug, is one that is included in a clinical study for the purpose of making comparisons of its performance in a defined population. Comparisons may be made in terms of a combination of factors such as:

- efficacy
- safety
- ease of use
- patient compliance

Comparators should not be confused with placebos. (Placebos are inert representations of an investigational compound designed to eliminate psychosomatic effects from statistical analyses.)

Comparator drugs are usually sought for the purpose of comparing a drug from one organization (the sponsor organization's proprietary investigational drug) with existing marketed products from other organizations. The objective of the comparison is to demonstrate the benefits of the sponsor organization's drug, based on factors such as those listed. This is intended to allow legitimate claims regarding, e.g., greater efficacy or an improved safety profile, for the sponsor organization's drug.

The sourcing of comparator drugs is, therefore, usually conducted confidentially by the sourcing organization based on commercial sensitivity. For example, if Company A learns that Company B is planning to take over the position of their drug within a particular market segment, Company A may change their pipeline strategy or make new plans in response to this information.

There is a global trend regarding the increasing importance of comparative trials. Data from comparative trials have been the focus of healthcare technology appraisal organizations worldwide. Such organizations can provide guidance on the medication that doctors from their country should be prescribing. This can be based on available evidence relative to the benefits, and may be described in terms of functional outcomes and improvements in quality of life versus the comparative costs of the drug and its alternatives.

Comparative effectiveness is expected to help deliver better value and lower costs as part of an overall healthcare reform effort. At the time of publication, a major initiative is underway. The American Recovery and Reinvestment Act of 2009 [1] has invested \$1.1 billion to begin the work of Comparative Effectiveness Research (CER) and the US Department of Health and Human Services has established a new Federal Coordinating Council to help coordinate research and guide investment. Physicians, pharmacists, patients, and purchasers of healthcare, including employers, health plans, and the government, are seeking evidence regarding the comparative effectiveness of drugs in order to make more knowledgeable and informed decisions.

1.2 Scope

1.2.1 *Comparator Sourcing Process*

The ISPE Good Practice Guide: Comparator Management discusses:

- selection of a comparator: branded or generic version